Feed TLRY
TL

Tilray Brands, Inc.

TLRY · NASDAQ

$4.02 -1.23% (-$0.05)
1M -12.04%
Market Cap $449.6M
P/E Ratio -
Div. Yield -
ROE 7.95%
Analiză

Un raport AI despre afacere, finanțe, evaluare, sentiment, știri și riscuri - scris în câteva minute.

Piotroski F-Score Weak
3/9
Valuation
44 /100
Fair
EV/EBITDA 38.36x
P/B 0.28x
P/S 0.39x
Growth
26 /100
Declining
Rev. growth 2.72%
Book val. growth 28.77%
EPS growth N/A
Profitability
10 /100
Weak
Gross margin 27.57%
FCF margin 9.87%
Net margin 12.90%
Quality
6 /100
Poor
ROIC 3.46%
Asset turnover 0.50x
ROE 7.95%
Debt
45 /100
Moderate
Debt/Equity 0.25x
Net debt/EBITDA 10.63x
Current ratio 2.21x
Stability
15 /100
Unstable
Beta 1.92x
Profitable years 0
Rev. volatility 23.02%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre TLRY
Online

Despre companie

Tilray Brands, Inc. is an international company specializing in the production and distribution of medicinal cannabis products and related goods. The company focuses on the cultivation, processing, and manufacturing of medical cannabis with an emphasis on quality and safety. Tilray Brands offers various forms of cannabis products, including therapeutic oil, capsules, flowers, and other preparations designed for medicinal purposes. The company collaborates with physicians and patients to provide high-quality and effective treatment options for various medical conditions. Tilray Brands is also engaged in research and development of new cannabis medicines and therapies. The company is following the growing interest in medicinal cannabis and its potential to improve the health of patients. Tilray Brands, Inc. (TLRY or TLB) shares could be an interesting choice for investors who follow the market for medicinal cannabis products and seek investment opportunities in an international company with a specialized focus on medical cannabis.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Irwin David Simon

Employees

3,595

Headquarters

Leamington

Evenimente viitoare

08 OCT.

Earnings

Upcoming earnings report

9d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.